- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT05075096
Long Term Outcome in ICU Treated COVID-19: New Chronic Diseases
Additional chronic diseases one year after intensive care unit (ICU) admission with Coronavirus disease 2019 (COVID-19) will be assessed in comparison to two control cohorts.
The ICU population comprises all Swedish ICU patients with COVID-19 with at least one year of follow up. The hospital admitted cohort comprises four hospital admitted patients with COVID-19 per ICU patient, matched on age, legal gender and region. The general population controls are matched to the ICU patients in a one to four fashion on age, legal gender and region.
ICU patients are identified in the Swedish intensive care registry. The hospital admitted patients are identified in the national patient registry and the population controls are identified in the population registry. Data on comorbidity, medications and death are provided from the National board of health and welfare.
Aperçu de l'étude
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
-
Uppsala, Suède, 79182
- Uppsala University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Admitted to a Swedish ICU and registered in the Swedish intensive care registry with the ICD 10 diagnosis U07.1 before 1 July 2020. ICU-cohort.
or randomly selected from all patients admitted to hospital but not ICU with the ICD 10 diagnosis U07.1 in the national patient registry, matched on age, legal gender and region (four per ICU patient) before 1 July 2020. Hospital cohort.
or randomly selected from the general population (and not included in the ICU or hospital admitted cohorts), matched on age, legal gender and region (four per ICU patient)
Exclusion Criteria:
- Missing a Swedish personal identification number
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Cohortes et interventions
Groupe / Cohorte |
Intervention / Traitement |
---|---|
Cohorte de contrôle des admissions hospitalières COVID-19
Quatre patients témoins aléatoires par patient en soins intensifs appariés selon l'âge légal, le sexe et la région.
Témoins sélectionnés parmi tous les patients admis dans un hôpital suédois avec COVID-19 avec au moins un an de suivi.
N'inclut pas les patients de la cohorte de soins intensifs COVID-19.
COVID-19 défini par le diagnostic U07.1 de la CIM-10 dans le registre national suédois des patients.
|
No intervention observational study.
|
Cohorte témoin population générale
Quatre contrôles de la population générale par patient en soins intensifs, appariés sur l'âge, le sexe légal et la région tirés du registre de la population totale de la Suède.
Non compris les soins intensifs et les patients COVID-19 admis à l'hôpital.
|
No intervention observational study.
|
COVID-19 ICU cohort
All patients admitted to a Swedish ICU with COVID-19 with at least one year of follow up.
COVID-19 defined by the ICD-10 diagnosis U07.1 in the nationwide Swedish intensive care registry.
|
No intervention observational study.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Is the illness severity in COVID-19 (according to level of care cohort) an independent risk factor for incident chronic renal failure within one year after inclusion?
Délai: One year
|
Variables in binary logistic model with the outcome incident chronic renal failure: On sick leave one year before ICU admission, age, legal gender, highest education, immigrant background, income the year before inclusion, marital status co-morbid diabetes mellitus.
Interaction with a variable denoting cohort (ICU, Hospital or General population) is added to all variables.
A significant interaction indicates a differential effect between cohorts.
|
One year
|
Is the illness severity in COVID-19 (according to level of care cohort) an independent risk factor for incident pulmonary disease within one year after inclusion?
Délai: One year
|
Variables in binary logistic model with the outcome incident pulmonary disease: On sick leave one year before ICU admission, age, legal gender, highest education, immigrant background, income the year before inclusion, marital status.
Interaction with a variable denoting cohort (ICU, Hospital or General population) is added to all variables.
A significant interaction indicates a differential effect between cohorts.
|
One year
|
Is the illness severity in COVID-19 (according to level of care cohort) an independent risk factor for incident cardiac failure within one year after inclusion?
Délai: One year
|
Variables in binary logistic model with the outcome incident cardiac failure: On sick leave one year before ICU admission, age, legal gender, highest education, immigrant background, income the year before inclusion, marital status co-morbid ischemic heart disease.
Interaction with a variable denoting cohort (ICU, Hospital or General population) is added to all variables.
A significant interaction indicates a differential effect between cohorts.
|
One year
|
Is the illness severity in COVID-19 (according to level of care cohort) an independent risk factor for incident pulmonary hypertension within one year after inclusion?
Délai: One year
|
Variables in binary logistic model with the outcome incident pulmonary hypertension: On sick leave one year before ICU admission, age, legal gender, highest education, immigrant background, income the year before inclusion, marital status co-morbid chronic obstructive pulmonary disease.
Interaction with a variable denoting cohort (ICU, Hospital or General population) is added to all variables.
A significant interaction indicates a differential effect between cohorts.
|
One year
|
Is the illness severity in COVID-19 (according to level of care cohort) an independent risk factor for being diagnosed with Post COVID (ICD-10, U09.9) within one year after inclusion?
Délai: One year
|
Variables in binary logistic model with the outcome Post COVID: On sick leave one year before ICU admission, age, legal gender, highest education, immigrant background, income the year before inclusion, marital status.
Interaction with a variable denoting cohort (ICU, Hospital or General population) is added to all variables.
A significant interaction indicates a differential effect between cohorts.
|
One year
|
Is the illness severity in COVID-19 (according to level of care cohort) an independent risk factor for incident psychiatric disease within one year after inclusion?
Délai: One year
|
Variables in binary logistic model with the outcome incident psychiatric disease: On sick leave one year before ICU admission, age, legal gender, highest education, immigrant background, income the year before inclusion, marital status.
Interaction with a variable denoting cohort (ICU, Hospital or General population) is added to all variables.
A significant interaction indicates a differential effect between cohorts.
|
One year
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
---|---|---|
Is the prevalence of pulmonary disease, chronic renal failure, pulmonary hypertension, cardiac failure or psychiatric diseases more common one year after than before ICU admission with COVID-19?
Délai: One year
|
Analyzed in the ICU admitted cohort.
|
One year
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Miklos Lipcsey, Professor, 202100-2932
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Processus pathologiques
- Infections à coronavirus
- Infections à Coronaviridae
- Infections à Nidovirales
- Infections par virus à ARN
- Maladies virales
- Infections
- Infections des voies respiratoires
- Maladies des voies respiratoires
- Pneumonie virale
- Pneumonie
- Maladies pulmonaires
- Attributs de la maladie
- COVID-19 [feminine]
- Maladie chronique
Autres numéros d'identification d'étude
- U1111-1269-6916
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Covid19
-
Anavasi DiagnosticsPas encore de recrutement
-
Ain Shams UniversityRecrutement
-
Israel Institute for Biological Research (IIBR)Complété
-
Colgate PalmoliveComplété
-
Christian von BuchwaldComplété
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActif, ne recrute pas
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitätsspital ZürichInscription sur invitation
-
Alexandria UniversityComplété
Essais cliniques sur No intervention.
-
Otsuka Pharmaceutical Factory, Inc.CelerionComplété
-
University of MinnesotaComplété
-
Assistance Publique - Hôpitaux de ParisComplété
-
Milton S. Hershey Medical CenterPas encore de recrutementMaladies du foie | NASH - Stéatohépatite non alcoolique | NASH
-
University of CologneComplétéAccident vasculaire cérébral | ApraxieAllemagne
-
Northwestern UniversityComplétéLa dépression | AnxiétéÉtats-Unis
-
H2O Health and Agriculture LLCInconnuePneumonie | DiarrhéeGuatemala
-
Eunah Cho, MDComplétéRécupération postopératoireCorée, République de
-
University of California, Los AngelesInconnue
-
Johns Hopkins UniversityAstraZenecaInscription sur invitationCancer du poumon non à petites cellules (NSCLC)États-Unis